The cancer immunotherapy market may be young, but it's about to get growing quickly. According to a new report from Decision Resources Group, the market is set to balloon from $1.1 billion in 2012 to nearly $9 billion in 2022 in the U.S., France, Germany, Italy, Spain, the U.K. and Japan. Taken with Bristol-Myers Squibb's ($BMY) Yervoy, immune checkpoint inhibitors--like BMS' nivolumab and Merck's ($MRK) pembrolizumab--will lead the way, capturing an 85% share of the market. But therapeutic vaccines will make their mark, too, with major-market sales reaching $1.2 billion. Release